Company
Regeneron
Regeneron is a biotechnology company that develops and commercializes medicines for treating various diseases, including rare diseases and cancer.
Why it’s in the news: It is in the news due to a recent FDA approval for a rare disease drug and a new deal in the radiopharma space.
Latest on Regeneron
- STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
- STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
- Regeneron wades into radiopharma through $40M upfront deal with Telix
- STAT+: FDA approves Ultragenyx gene therapy
- Fact Sheet President Donald J Trump Announces Deal With Regeneron To Bring Most Favored Na
Connections
6 entities linked to Regeneron across the news graph.
Under pressure from (1)